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Supplementary Materials and Methods
Immunohistochemistry (IHC) for liver and spleen. IHC was performed using EnVision IHC kit following the manufacturer's protocol (Agilent) . N protein was stained using a rabbit anti-CCHFV N protein (IBT Bioservices, 1:5000). Cells were counterstained with hematoxylin.
Binding of antibody to CBD-GP38. For this we exploited a poxvirus protein in which one region of that molecule, termed the cell binding domain (CBD), can bind to mammalian cell surfaces. GP38 from CCHFV strain IbAr10200 was de novo synthesized in-frame with the C-terminal end of the CBD. The resultant gene construction (CBD-GP38) was transfected into 293T cells using Fugene 6 along with a negative control plasmid derived from Junin virus GP1 (CBP-GP1) (41). After three days, cells were harvested, washed in FACS buffer [PBS +5% fetal bovine serum (FBS)]. Cells were incubated with the indicated sera at a concentration of 1:100 diluted in FACS buffer for 1 h at 37°C. Cells were washed three times in FACS buffer and pelleted via low speed centrifugation. Cells were then incubated with a species specific secondary antibody conjugated to Alexa Fluor 488 (1:500) for 30 m at 37°C. Samples were then washed three times and resuspended in fresh FACS buffer and the interactions of various antibodies were evaluated by flow cytometry. Flow cytometry was performed on a FACSCalibur flow cytometer (Becton Dickinson). Data were collected and analyzed using FlowJo software (Tree Star INC; Ashland, OR). A total of 10,000 cells were analyzed for each sample using a live-gate.
Vaccination of mice against CCHFV M-segment. Mice were vaccinated as described in (25). C57BL/6 mice were vaccinated in the anterior tibialis muscle with 25 µg of the CCHFV-M co-DNA vaccine (IbAr10200) using the Ichor TriGrid® IM-EP system, under isoflurane anesthesia. All mice were vaccinated three times at three weeks intervals. Blood was obtained via submandibular bleeds three weeks after the third vaccination.
CCHF VLP Production. CCHF VLPs production of IbAr10200 strain (CCHF VLP ) was performed as reported previously (25). Briefly, BHK-21 cells were transfected with 10 µg pC-M Opt (IbAr10200), 4 µg PC-N, 2 µg L-Opt, 4 µg T7-Opt, and 1 µg Nano-luciferase encoding minigenome plasmid using the Transit LT-1 transfection reagent according to the manufacturer's instructions (Mirus Bio). Supernatants were harvested on day 3 post-transfection and clarified by low speed centrifugation. Subsequently, VLPs were pelleted through a cushion of 20% sucrose in virus resuspension buffer (VRB; 130 mM NaCl, 20 mM HEPES, pH 7.4) by centrifugation for 2 h at 106,750 x g in an SW32 rotor at 4ºC and then resuspended in 1:200 volume of VRB at 4°C. VLPs were frozen at -80°C in single-use aliquots. Individual lots of CCHF VLP were standardized by Western Blot analysis based on incorporation of N relative to a parallel gradient of recombinant N loaded on the same SDS-PAGE reducing gel. CCHF VLP was quantified using a TCID50 assay on SW13 cells in 96-well, black-walled, clear-bottom plates (Costar). Plates were incubated with tenfold dilutions of the CCHF VLP overnight and were then processed for Nano Luciferase (Promega) expression. Wells that displayed a Nano Luciferase signal 3 standard deviations or greater above background levels were considered positive for VLP signal. VLP stock concentrations (TCID 50 per mL) were calculated as previously described (25).
CCHFV VLP neutralization assay. VLP neutralization was performed as described previously (25). Briefly, 24 h prior to use, 50,000 SW13 cells were seeded into a 96 well black-walled tissue culture plate. The indicated antibodies were half-log serially diluted (from 1:25 to 1:25,368) and then an equal volume of medium with IbAr10200 VLPs containing 237 TCID 50 units was added and incubated at 37°C/5% CO 2 for 1 h. For some samples, 5% Low-Tox Guinea Pig Complement was included in the dilution (Cederlane labs). Half of this reaction mixture (50 µl) was then added to the previously aspirated target cell plate. Cells were incubated for 24 h before being lysed using NanoGlo Lysis buffer mixed with 1:50 dilution of NanoGlo substrate (Promega). Samples were mixed and incubated for 5 min at ambient temperature prior to the luminescent signal being measured on a Modulus Microplate Reader (Turner Biosystems) with an integration time of 5 s per well. VLP neutralization (80% inhibition) was generated for each mAb as previously described (34) both with and without 5% rodent complement. The reciprocal value of the mAb concentration corresponding to the VLPNeut80 was then calculated (e.g. mAb with a VLPNeut80 of 1 µg/ml would be reported as 1, 10 µg/ml as 0.1, etc). Data were analyzed as previously reported using GraphPad Prism software (25).
VLP Octet interactions.
A premix competition assays was used for binning the three CCHFV monoclonal antibodies (11E7, 10E11, 13G8). The premix competition assay consisted of four parts. Part one was to bind the stationary antibody onto a sensor. Part two was to premix the saturating antibody with biotinylated CCHF VLPs and incubate. Part three was to expose the sensors with the premix solution. Part four was to obtain a baseline response followed by response of the sensors in the amplification wells. CCHF VLPs at a concentration of 10 µg/mL were mixed with a saturating antibody at 20 µg/mL concentration for 20 m using the Octet QKe. A null antibody (anti-EBOV GP-H3C8) was also included and a well with no antibody as a negative control well. The incubation step was performed at 30°C with a shaking rate of 1000 RPM.
Part three: Expose sensors with premix solutions.
All of the following steps were performed at 300 RPM and 30°C on the Octet QKe. The sensors were blocked for 3 m using a solution of Kinetics buffer with 0.1% goat serum (SeraCare). The sensors were then washed for 60 seconds in well of Kinetics buffer. The sensors were then moved to the premixed solutions of VLPs with antibodies or controls. The premix and sensors were incubated together for 30 m on the Octet, followed by another 3 minute block in Kinetics buffer with 0.1% Goat sera and a one minute wash in Kinetics Buffer.
Part four: Baseline and Signal amplification
All of the following steps were performed at 300 RPM and 30°C on the Octet QKe. The sensors were incubated in wells containing Streptavidin HRP (Sigma) 0.05% in Kinetics buffer for five minutes. Sensors were then moved to wells with Kinetics buffer for two minutes. The binding average from last ten seconds of the kinetics step was used as the baseline for the following step. The sensors were then placed in DAB solution (ThermoFisher). The DAB solution makes a precipitate on the sensor surface in the presence of HRP. The precipitate amplifies the binding signal, which indicates any binding activity that occurred during the interrogation step. Fig. S1 . Representative immunohistochemistry stain for CCHFV N protein in livers and spleens of mice. The indicated tissue sections from infected 13G8 or isotype control mice or uninfected control mice treated with 13G8 were stained for viral N protein as described above. Cells were counterstained with hematoxylin. Fig. S2 . GP38 amino acid differences between CCHFV strains IbAr 10200 and Afg09-2990. CCHFV GP38 amino acid differences from the indicated strains were determined using MegAlign Ver. 13.0.0 (DNAstar software). Only amino acid differences are shown on the Af09-2990 sequence Fig. S3 . Combined ISH analysis of CCHFV strain IbAr 10200-and Afg09-2990-infected mice treated with mAb-13G8. CCHFV RNA ISH analysis was performed as in Fig. 1 and Fig. 3C . Cells were counterstained with hematoxylin. With the exception of the uninfected controls, sections in this figure are from different animals from the figures in the main manuscript. Fig. S4 . Combined hematoxylin and eosin liver analysis of CCHFV strain IbAr 10200-and Afg09-2990-infected mice treated with mAb-13G8. H&E staining from livers of CCHFV infected mice was performed as in Fig. 1D and Fig. 3D . With the exception of the uninfected controls, sections in this figure are from different animals from the figures in the main manuscript. Box shows the approximate area of enlargement. Arrows point to inflammation and hepatocellular necrosis. Arrowheads note hepatocytes that exhibit lipid-type degeneration. A. To determine if 10E11 and 13G8 antibodies bound GP38, we fused the coding region with a domain of a poxvirus protein that binds to cell surfaces. The resultant construct termed CBD-GP38 was transfected into 293T cells and the interaction of various antibodies with these cells, or cells transfected with an arenavirus GP1-CBD molecule (41), were evaluated by flow cytometry. We found that mAb-13G8 and mAb-10E11 both interacted with CBD-GP38 on cell surfaces, but G C -targeting antibodies mAb-8A1 and mAb-11E7 did not. No antibody bound the negative control cells. B. Antibody competition between three CCHFV mAbs for binding on IbAr 10200 CCHF VLPs was assessed by analysis on the Octet platform. Presence of strong epitope competition (pink), weak competition (yellow), and no competition (green) are indicated on table. C. Octet-based affinity analysis of CCHFV mAb interaction with recombinant GP38. D. IFNAR -/-mice (n=10 per group) were infected with 100 PFU CCHFV strain IbAr10200 by the SC route. Mice were injected with indicated antibodies by the IP route on day -1 (1mg/dose). As a control mice were treated with an isotype control antibody. Survival and percent group weight change were recorded. Fig. S8 . CCHF VLP neutralization by select mAbs with and without complement. VLP neutralization (80% inhibition) was generated for each mAb as previously described (25, 34) both with and without 5% rodent complement. The reciprocal value of the mAb concentration corresponding to the VLPNeut 80 was then calculated (e.g. mAb with a VLPNeut 80 of 1 µg/ml would be reported as 1, 10 µg/ml as 0.1, etc).
Fig. S9
. GP38 binding of mouse and rabbit sera. A. Mouse sera was produced by DNA vaccination as described in (25). For a GP38 target, 293T cells were transfected CBP-GP38 as in SFig. 3. Transfected cells were incubated with pooled sera from vaccinated mice (1:100) and then incubated with a secondary anti-mouse antibody conjugated with Alexafluor488 (1:500), each color represents a pool of sera. Cells were washed and examined by flow cytometry. Sera from unvaccinated animals was used as a control (grey solid). B. Sera was produced in rabbits (n=2) by DNA vaccination with the M-segment DNA plasmid as described in the main manuscript. GP38his was plated in the wells of a 96-well plate (500 ng/well). The indicated mAbs were serially diluted tenfold (from 1:100) and incubated with purified protein, then incubated with a secondary anti-rabbit antibody conjugated with HRP (1:1000). Endpoint titers were determined as the highest dilution with an absorbance value greater than the mean absorbance value from negative control antibodies plus three standard deviations. The dashed line indicates the limit of detection.
Increased surface interaction
Mouse sera CBP-GP38 A B Table S1 . Histopathology summary.
a 0=lesion not present; 1=minimal; 2=mild; 3= moderate; 4=marked; 5=severe
